4.6 Article

Impact of [18F]-fluoro-ethyl-tyrosine PET imaging on target definition for radiation therapy of high-grade glioma

Journal

NEURO-ONCOLOGY
Volume 17, Issue 5, Pages 757-763

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/neuonc/nou316

Keywords

FET-PET; glioma; MRI; radiation therapy; target definition

Funding

  1. Lundbeck Foundation

Ask authors/readers for more resources

Background. We sought to assess the impact of amino-acid F-18-fluoro-ethyl-tyrosine (FET) positron emission tomography (PET) on the volumetric target definition for radiation therapy of high-grade glioma versus the current standard using MRI alone. Specifically, we investigated the influence of tumor grade, MR-defined tumor volume, and the extent of surgical resection on PET positivity. Methods. Fifty-four consecutive high-grade glioma patients (World Health Organization grades III-IV) with confirmed histology were scanned using FET-PET/CT and T1 and T2/fluid attenuated inversion recovery MRI. Gross tumor volume and clinical target volumes (CTVs) were defined in a blinded fashion based on MRI and subsequently PET, and volumetric analysis was performed. The extent of the surgical resection was reviewed using postoperative MRI. Results. Overall, for similar to 90% of the patients, the PET-positive volumes were encompassed by T1 MRI with contrast-defined tumor plus a 20-mm margin. The tumor volume defined by PET was larger for glioma grade IV (P,. 001) and smaller for patients with more extensive surgical resection (P = .004). The margin required to be added to the MRI-defined tumor in order to fully encompass the FET-PET positive volume tended to be larger for grade IV tumors (P = .018). Conclusion. With an unchanged CTV margin and by including FET-PET for gross tumor volume definition, the CTV will increase moderately for most patients, and quite substantially for a minority of patients. Patients with grade IV glioma were found to be the primary candidates for PET-guided radiation therapy planning.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Daily Adaptive Proton Therapy: Is it Appropriate to Use Analytical Dose Calculations for Plan Adaption?

Lena Nenoff, Michael Matter, Agnes Geetanjali Jarhall, Carla Winterhalter, Jenny Gorgisyan, Mirjana Josipovic, Gitte F. Persson, Per Munck af Rosenschold, Damien Charles Weber, Antony John Lomax, Francesca Albertini

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)

Review Oncology

Recent advances of PET imaging in clinical radiation oncology

M. Unterrainer, C. Eze, H. Ilhan, S. Marschner, O. Roengvoraphoj, N. S. Schmidt-Hegemann, F. Walter, W. G. Kunz, P. Munck af Rosenschold, R. Jeraj, N. L. Albert, A. L. Grosu, M. Niyazi, P. Bartenstein, C. Belka

RADIATION ONCOLOGY (2020)

Article Oncology

Residual positioning errors and uncertainties for pediatric craniospinal irradiation and the impact of image guidance

Daniel Gram, Andre Haraldsson, N. Patrik Brodin, Karsten Nysom, Thomas Bjork-Eriksson, Per Munck af Rosenschold

RADIATION ONCOLOGY (2020)

Article Environmental Sciences

Promoting Evidence-Based Practice for Improved Occupational Safety and Health at Workplaces in Sweden. Report on a Practice-Based Research Network Approach

Irene B. Jensen, Elisabeth Bjork Bramberg, Charlotte Wahlin, Christina Bjorklund, Ulric Hermansson, Malin Lohela Karlson, Liselotte Schafer Elinder, Peter Munck af Rosenschold, Tarja Nevala, Ned Carter, Bodil Mellblom, Lydia Kwak

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2020)

Article Multidisciplinary Sciences

Multimodal soft tissue markers for bridging high-resolution diagnostic imaging with therapeutic intervention

Anders E. Hansen, Jonas R. Henriksen, Rasmus Jolck, Frederikke P. Fliedner, Linda M. Bruun, Jonas Scherman, Andreas Jensen, Per Munck Af Rosenschold, Lilah Moorman, Sorel Kurbegovic, Steen R. de Blanck, Klaus R. Larsen, Paul F. Clementsen, Anders N. Christensen, Mads H. Clausen, Wenbo Wang, Paul Kempen, Merete Christensen, Niels-Erik Viby, Gitte Persson, Rasmus Larsen, Knut Conradsen, Fintan J. McEvoy, Andreas Kjaer, Thomas Eriksen, Thomas L. Andresen

SCIENCE ADVANCES (2020)

Article Radiology, Nuclear Medicine & Medical Imaging

AAPM Task Group 264: The safe clinical implementation of MLC tracking in radiotherapy

Paul J. Keall, Amit Sawant, Ross Berbeco, Jeremy T. Booth, Byungchul Cho, Laura Cervino, Eileen Cirino, Sonja Dieterich, Martin F. Fast, Peter B. Greer, Per Munck Af Rosenschold, Parag J. Parikh, Per Rugaard Poulsen, Lakshmi Santanam, George W. Sherouse, Jie Shi, Sotirios Stathakis

Summary: MLC tracking is a widely available radiotherapy technology that has been extensively researched and implemented, providing the radiation oncology community with new clinical implementation guidelines and quality assurance recommendations.

MEDICAL PHYSICS (2021)

Article Oncology

The risk of late effects following pediatric and adult radiotherapy regimens in Hodgkin lymphoma

Anni Young Lundgaard, Lisa Lyngsie Hjalgrim, Laura Ann Rechner, Michael Lundemann, N. Patrik Brodin, Morten Joergensen, Lena Specht, Maja Vestmoe Maraldo

Summary: The study analyzed adolescent young adults with Hodgkin lymphoma treated with radiation therapy according to pediatric or adult protocols. It found that patients on pediatric regimens had more advanced disease, leading to higher risks of radiation-induced late effects and corresponding life years lost compared to adult regimens.

STRAHLENTHERAPIE UND ONKOLOGIE (2021)

Article Oncology

Establishment and Initial Experience of Clinical FLASH Radiotherapy in Canine Cancer Patients

Elise Konradsson, Maja L. Arendt, Kristine Bastholm Jensen, Betina Borresen, Anders E. Hansen, Sven Back, Annemarie T. Kristensen, Per Munck af Rosenschold, Crister Ceberg, Kristoffer Petersson

Summary: The study of FLASH radiotherapy in canine cancer patients showed promising feasibility and efficacy, with proper dose control and safety monitoring in place. Adverse events were mild and manageable, paving the way for further research in veterinary and human clinical trials.

FRONTIERS IN ONCOLOGY (2021)

Article Oncology

Pelvic U-Net: multi-label semantic segmentation of pelvic organs at risk for radiation therapy anal cancer patients using a deeply supervised shuffle attention convolutional neural network

Michael Lempart, Martin P. Nilsson, Jonas Scherman, Christian Jamtheim Gustafsson, Mikael Nilsson, Sara Alkner, Jens Engleson, Gabriel Adrian, Per Munck af Rosenschold, Lars E. Olsson

Summary: This study developed a deep learning model, named Pelvic U-Net, for the automated and improved segmentations of organs at risk (OAR) in the pelvic region. The model showed credible and clinically applicable results, with improved performance compared to previous studies. Additionally, the model reduced segmentation time by 70%, allowing for an accelerated radiation therapy treatment planning workflow for anal cancer patients.

RADIATION ONCOLOGY (2022)

Article Oncology

Transitioning from conventional photon therapy to proton therapy for primary brain tumors

Hanna Ek, Ingrid Fagerstrom Kristensen, Lars Stenberg, Sara Kinhult, Hunor Benedek, Simon Ek, Svend Aage Engelholm, Silke Engelholm, Per Munck af Rosenschold

Summary: This study investigated the characteristics and treatment outcomes of patients selected for proton radiation therapy (PT) for lower-grade gliomas. The study found no difference in the risk of pseudo-progression (PsP) between PT and photon therapy (XRT), and PT was associated with lower rates of fatigue within three months after treatment and better survival outcomes.

ACTA ONCOLOGICA (2023)

Article Oncology

The risk of radiation-induced neurocognitive impairment and the impact of sparing the hippocampus during pediatric proton cranial irradiation

Daniel Gram, N. Patrik Brodin, Thomas Bjork-Eriksson, Karsten Nysom, Per Munck af Rosenschold

Summary: This study investigated the risk of neurocognitive impairment caused by craniospinal irradiation (CSI) and the feasibility and effects of hippocampal sparing. The results show that by sparing the hippocampus, the risk of neurocognitive impairment can be significantly reduced without compromising tumor control.

ACTA ONCOLOGICA (2023)

Article Clinical Neurology

Neurocognitive development after pediatric brain tumor-a longitudinal, retrospective cohort study

Ingrid Tonning Olsson, Johan Lundgren, Lars Hjorth, Per Munck Af Rosenschold, Asa Hammar, Sean Perrin

Summary: This study aimed to statistically model neurocognitive development in survivors of pediatric brain tumors (PBTs), both irradiated and non-irradiated, and identify clinical variables associated with decline in neurocognitive scores. The study found that survivors of PBTs experience a decline in neurocognitive scores regardless of treatment received, indicating the need for routine screening for neurocognitive rehabilitation. However, survivors treated with whole-brain radiation therapy (WBRT) and/or ventriculo-peritoneal (VP) shunting showed a faster decline and are at higher risk for negative neurocognitive outcomes.

CHILD NEUROPSYCHOLOGY (2023)

Article Oncology

ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma

Maximilian Niyazi, Nicolaus Andratschke, Martin Bendszus, Anthony J. Chalmers, Sara C. Erridge, Norbert Galldiks, Frank J. Lagerwaard, Pierina Navarria, Per Munck af Rosenschoeld, Umberto Ricardi, Martin J. van den Bent, Michael Weller, Claus Belka, Giuseppe Minniti

Summary: This guideline aims to update the existing European consensus on delineation of the clinical target volume (CTV) in adult glioblastoma patients. It discusses key issues including pre-treatment steps, target delineation, and technical aspects of treatment. Based on the EORTC recommendation, a single CTV definition using post-operative contrast-enhanced T1 abnormalities is recommended, without the need to cone down. The PTV margin should be based on individual mask system and IGRT procedures, usually no greater than 3 mm.

RADIOTHERAPY AND ONCOLOGY (2023)

Meeting Abstract Oncology

A deeply supervised convolutional neural network ensemble for multilabel segmentation of pelvic OARs

M. Lempart, M. P. Nilsson, J. Scherman, M. Nilsson, C. J. Gustafsson, C. J. Gustafsson, P. Munck af Rosenschold, L. E. Olsson

RADIOTHERAPY AND ONCOLOGY (2021)

Article Oncology

Volumetric modulated arc therapy dose prediction and deliverable treatment plan generation for prostate cancer patients using a densely connected deep learning model

Michael Lempart, Hunor Benedek, Christian Jamtheim Gustafsson, Mikael Nilsson, Niklas Eliasson, Sven Back, Per Munck af Rosenschold, Lars E. Olsson

Summary: A new study trained a deep learning model based on triplets to predict VMAT dose distributions for prostate cancer patients, showing improved accuracy and efficiency in dose predictions, which were successfully transformed into deliverable treatment plans. The research suggests that triplet-based training can enhance the accuracy and efficiency of VMAT dose predictions.

PHYSICS & IMAGING IN RADIATION ONCOLOGY (2021)

No Data Available